
Rising Defense Partner Reacts After Trump Threat
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
India has hit back at the United States in defense of its oil purchases from Russia after President Donald Trump issued a new threat of tariffs tied to the trade.
The U.S. State Department did not immediately respond to a request for comment outside of office hours.
Why It Matters
The increasing friction between India and the United States is in part an indication of the failure to reach a trade deal between the Trump administration and the world's most populous country and fastest growing top economy. Increasingly friendly U.S. relations with Indian rival Pakistan have been another irritant in the relationship.
But it also highlights a souring in a relationship that is key for global security, with India seen as a potential bulwark against China for the United States while pursuing a foreign policy that had traditionally been strongly independent.
What To Know
Trump issued a new threat of tariffs on India on Monday, linking it to India's purchases of Russian oil. It came at a time when Trump was seeking to increase pressure on Russia over its war in Ukraine, which has only increased in intensity despite the president's pledge to end it as soon as he took office.
The Indian national flag waves on National Flag Day, July 22, 2025, in front of the Tripura State Museum, Ujjayanta Palace, in Agartala.
The Indian national flag waves on National Flag Day, July 22, 2025, in front of the Tripura State Museum, Ujjayanta Palace, in Agartala.
Photo by ABHISEK SAHA/Middle East Images/AFP via Getty Images
India's External Affairs Ministry said in a statement that its purchases of oil from Russia were a necessity compelled by the state of the global market. It challenged criticism over the oil deals from both the United States and European Union.
"It is revealing that the very nations criticizing India are themselves indulging in trade with Russia. Unlike our case, such trade is not even a vital national compulsion," the statement from the ministry spokesperson said.
"Where the United States is concerned, it continues to import from Russia uranium hexafluoride for its nuclear industry, palladium for its EV industry, fertilizers as well as chemicals."
Ukraine Invasion
New Delhi said Washington had encouraged it to buy Russian oil after the invasion of Ukraine in 2022 to stabilize the global energy market.
It also said the EU's trade with Russia had been significantly bigger than India's. Russia has continued to make billions from energy exports despite Western sanctions to try to apply pressure over the Ukraine war.
"Europe-Russia trade includes not just energy, but also fertilizers, mining products, chemicals, iron and steel and machinery and transport equipment," it said.
"The targeting of India is unjustified and unreasonable. Like any major economy, India will take all necessary measures to safeguard its national interests and economic security."
In the absence of a trade deal with the United States, India has meanwhile been pursuing other agreements and strengthening its ties with China.
What People Are Saying
U.S. President Donald Trump on Truth Social: "India is not only buying massive amounts of Russian Oil, they are then, for much of the Oil purchased, selling it on the Open Market for big profits. They don't care how many people in Ukraine are being killed by the Russian War Machine. Because of this, I will be substantially raising the Tariff paid by India to the USA. Thank you for your attention to this matter!!! President DJT"
India's Ministry of External Affairs spokesperson: "India's imports are meant to ensure predictable and affordable energy costs to the Indian consumer. They are a necessity compelled by global market situation. However, it is revealing that the very nations criticizing India are themselves indulging in trade with Russia. Unlike our case, such trade is not even a vital national compulsion."
What Happens Next
India is unlikely to be swayed by U.S. pressure and in the absence of a trade deal is likely to continue to take an independent line. The worsening of the relationship between the United States and India could be to the benefit of U.S. rivals Russia and China as they also seek to cement India in their camp.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
"Another Day Of Reality Eroding Before Our Eyes": People Can't Believe Donald Trump Actually Made This Claim About Lowering Drug Prices
Donald Trump's math on cutting drug prices didn't add up. Again. The president this weekend repeated his promise to get pharma companies to lower the cost of medications for Americans, who often have to pay much more for certain drugs than people abroad. But the actual amount of the 'tremendous drop' in cost that Trump boasted about had critics scratching their heads. Related: 'You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500%,' Trump said. 'I don't mean 50%. I mean 14, 1,500%,' he added. But as many on social media pointed out, that would mean all drugs are free and people actually get paid to receive them. @Acyn / CNN / Via Also, drug prices haven't actually come down, despite Trump's pressure on pharmaceutical companies. Trump appeared to acknowledge that when he later said, 'We'll be dropping drug prices ... by 1,200, 1,300 and even 1,400% and 500% but not just 50% or 25%, which normally would be a lot because the rest of the world pays much less for the identical drug.' Related: Reality is 'eroding before our eyes,' said one critic. Others agreed. @JenniferEValent / CNN / Via @gtconway3d / CNN / Via @jjabbott / CNN / Via @greggnunziata / CNN / Via Related: @SedgeDienst / CNN / Via @AmoneyResists / CNN / Via @PWBaugh. CNN / Via @michaelpfreeman / Via @IsaacDovere / Via Related: @AuforGA / Via @WajahatAli / Via @svdate / Via This article originally appeared on HuffPost. Also in In the News: Also in In the News: Also in In the News:
Yahoo
7 minutes ago
- Yahoo
Tariffs are denting profits, and maybe soon your portfolio
The theme of the moment in financial markets is the resilience of US stock values. President Trump is imposing billions of dollars in new import taxes on US firms, yet the S&P 500 (^GSPC) index is up 26% from its April low and fresh off several record highs. Investors who shunned US assets just a few months ago are now aggressively buying. However, numerous warning signs have emerged during the second quarter earnings season as companies outline the ways Trump's tariffs are hurting profits, disrupting operations, and forcing price hikes onto consumers. Tariffs are not hitting every company, since they mainly affect goods, and many of America's top firms are service providers. But some analysts think the negative tariff effects are widespread enough to take the wind out of stocks soon. With second quarter earnings in for about two-thirds of S&P 500 companies, Yahoo Finance's Grace O'Donnell has identified more than four dozen large firms saying tariffs are impacting their businesses in some material way. Some are able to quantify the monetary effect on earnings. Others expect tariffs to hit their finances but aren't yet sure how. And some CEOs have been blunt about price hikes heading toward consumers. Manufacturers are bearing a large portion of the tariff cost, since many rely on imported components that are now more expensive. Caterpillar (CAT), Kimberly-Clark (KMB), BMW ( Ford (F), Harley-Davidson (HOG), Hyundai (HYMTF), Tesla (TSLA), GE Aerospace (GE), 3M (MMM), and General Motors (GM) are among the companies saying tariffs reduced earnings in the second quarter. Ford, as one example, said tariffs would knock $2 billion off earnings this year. Caterpillar expects a tariff hit of at least $1.3 billion. Kimberly-Clark's tariff loss will be around $170 million. Read more: The latest news and updates on Trump's tariffs It's not just manufacturers. Companies that import products they sell to consumers are suffering too. Apple (AAPL) expects tariffs to cut earnings by nearly $2 billion for the six months through Sept. 30. Hershey (HSY) said tariffs will cost it at least $170 million this year. VF Corp., whose brands include Vans, The North Face, and Timberland, sees a $250 million hit to earnings through 2026. Some of America's biggest consumer goods producers, including Procter & Gamble (PG), Mattel (MAT), Columbia Sportswear (COLM), and L'Oreal (LOR.F), say they'll have no choice but to pass some of their higher costs onto consumers. Many executives discussing the Trump tariffs say it's too soon to assess the impact of import taxes that have only been in place a couple of months, which means a lot more bad news may be in the pipeline. The disconnect in markets right now is that tariff impacts that are causing headline damage for a lot of individual companies don't yet seem to be depressing overall earnings. Roughly 80% of companies reporting their earnings so far have beaten analyst estimates, according to FactSet. That's better than the usual beat ratio. Earnings growth has also been solid, and Wall Street forecasts for the third quarter are even better, despite the tariffs. Solid actual earnings and robust forecasts for future gains are the driving forces motivating investors to buy. Read more: 5 ways to tariff-proof your financesThe question is will it last, and there are several reasons for doubt. Oxford Economics thinks investors are too bullish now because they were too panicky in April and May, when Trump imposed dramatically high tariffs that he has since lowered. Trump's "Liberation Day" tariff announcements on April 2 triggered a big stock sell-off, which in turn prompted Trump to back down and pause some of those tariffs. The average tariff rate jumped from 2.5% before Trump took office to about 28% after "Liberation Day." Recent changes to Trump's tariff regime brought the average import tax to as low as 14%, then up to about 18%, where it is today. So, the average import tax is now lower than it was in April and May — but still considerably higher than it's been for the past 90 years. That will still sting. "Margin resilience [is] unlikely to last," Oxford economists noted in an Aug. 5 analysis. "We think margin pressures will build throughout the second half of the year as the effective tariff rate continues to move higher, businesses deplete front-run inventories, and domestic demand softens." Bloomberg recently reported that several Wall Street money managers, including Morgan Stanley, Evercore ISI, and Deutsche Bank, are warning clients that a stock pullback of 10% to 15% could be on the horizon. Trump's trade wars are the biggest concern, as the rising toll of import taxes further damages profits, raises prices, reins in spending, and depresses growth. The sharp slowdown in job growth during the past three months may be a harbinger of worse to come. The average pace of job gains from May through July was just 35,000, an 80% decline from the 2024 pace. Trump got so angry over those numbers that he fired the government economist who oversees the employment report. But the real problem is Trump's own policies, and he can't fire every CEO who needs to explain how tariffs are harming profits. Rick Newman is a senior columnist for Yahoo Finance. Follow him on Bluesky and X: @rickjnewman. Click here for political news related to business and money policies that will shape tomorrow's stock prices.
Yahoo
7 minutes ago
- Yahoo
Pfizer CEO details talks with Trump administration on tariffs, Most Favored Nations pricing
Pfizer (PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the COVID-19 pandemic when the two were in regular contact to help speed up vaccine production. That relationship, he said, has created a direct line to discuss some of the headwinds the company faces out of Washington, D.C. In his second term, Trump is targeting the drug industry for high prices and overseas production — threatening tariffs as high as 250% on imported drugs. But Bourla told Yahoo Finance he believes Trump and other officials in D.C. are having productive conversations with industry leaders about tariffs and drug pricing. "I think [Trump] is educated, of course he doesn't go into the details, it's not his job, but he understands the dynamics [of the industry]," Bourla said. When asked about the tariff threat, Bourla shared his understanding from his ongoing discussions. "I don't want to speak for the president, but what he said today, which was very important also, was that it would be a very small tariff in the first couple of years. And then he opened the window for a grace period. Because I had this discussion with him and I had this discussion with multiple other members of the administration," Bourla said. Read more: What Trump's tariffs mean for the economy and your wallet The industry is awaiting the results of an investigation by the administration into how those tariffs will be implemented — and Bourla said the devil will be in the details. Currently, more than 90% of prescriptions in the US are from generics, which are often the cheapest drug type. Branded drugs are often the most expensive and are largely produced in the US. But some early components of the manufacturing process, key chemicals known as active pharmaceutical ingredients (APIs), are often made overseas in Europe or Asia. That will be important to understand when the final ruling for the tariffs is made. "We need to understand if the API will dictate the country of origin, or where the final product is made," Bourla said. Pfizer is also one of the companies that received a letter from Trump last week detailing demands to reduce prices for Medicare and Medicaid enrollees to match the lowest price paid by developing nations, known as Most Favored Nations (MFN). The company is currently planning for the implementation of reduced prices, as well as working on how to mitigate negative impacts, Bourla said. "We are still discussing it with the president. ... The devil could be in the details in these stages," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data